QCG
MRSN

Quadrant Capital Group’s Mersana Therapeutics MRSN Stock Holding History

Quadrant Capital Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5
Closed -$477 – 2743
2023
Q1 		$477 Buy
+5
New +$702 ﹤0.01% 2612

Other funds holding MRSN

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Quadrant Capital Group's MRSN Position: Q2 2023 in Review

Quadrant Capital Group sold out of Mersana Therapeutics (MRSN) in Q2 2023, closing a stake of 5 shares — an estimated $477 sold.

Quadrant Capital Group first reported a position in MRSN in Q1 2023 and held it in 1 quarter. The position peaked at $477 in Q1 2023. 147 funds tracked by Wall St. Rank hold MRSN as of Q2 2023.

  • Quadrant Capital Group reported no remaining Mersana Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 5 Mersana Therapeutics shares in Q2 2023, an estimated $477.
  • Quadrant Capital Group first reported a position in Mersana Therapeutics in Q1 2023 and held it in 1 quarter.
  • Quadrant Capital Group's Mersana Therapeutics position peaked at $477 in Q1 2023.
  • 147 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2023.

Based on Quadrant Capital Group's 13F filing for Q2 2023, filed 10 Aug 2023.